Actavis Investor Day 013114

Lisa
DeFrancesco
VP, Global
Investor Relations
Actavis Cautionary Statement Regarding Forward-Looking Statements
Forward-Looking Statement
Statements contained in this presentation that refer to Actavis estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect
Actavis current perspective of existing trends and information as of the date of this presentation. Forward looking statements generally will be accompanied by words such
as "anticipate," "believe," "plan," "could," "should," "estimate," "expect," "forecast," "outlook," "guidance," "intend," "may," "might," "will," "possible," "potential," "predict,"
"project," preliminary or other similar words, phrases or expressions. For instance, any statements in this presentation concerning prospects related to Actavis strategic
initiatives, product introductions and anticipated financial performance are forward-looking statements. It is important to note that Actavis goals and expectations are not
predictions of actual performance. Actavis performance, at times, will differ from its estimates, goals and expectations. Actual results may differ materially from Actavis
current estimates and expectations depending upon a number of factors affecting Actavis business. These factors include, among others, the inherent uncertainty
associated with financial projections; variability of revenue mix between Actavis Pharma, Specialty Brands, and Distribution business units; successful integration of
strategic acquisitions and the ability to recognize the anticipated synergies and benefits of such acquisitions; the difficulty of predicting the timing and outcome of pending or
future litigation and government investigations and risks that an adverse outcome in such litigation or investigations could render Actavis liable for substantial damages or
penalties; the impact of competitive products and pricing; risks related to fluctuations in foreign currency exchange rates; periodic dependence on a small number of
products for a material source of net revenue or income; variability of trade buying patterns; changes in generally accepted accounting principles; risks that the carrying
values of assets may be negatively impacted by future events and circumstances; the timing and success of product launches; the difficulty of predicting the timing or
outcome of product development efforts and regulatory agency approvals or actions, if any; risks and uncertainties normally incident to the pharmaceutical industry,
including product liability claims and the availability of product liability insurance on reasonable terms; market acceptance of and continued demand for Actavis products;
difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with governmental regulations
applicable to Actavis facilities, products and/or businesses; changes in the laws and regulations, including Medicare, Medicaid, and similar laws in foreign countries
affecting, among other things, pricing and reimbursement of pharmaceutical products and the settlement of patent litigation; risks that resolution of patent infringement
litigation through settlement could result in investigations or actions by private parties or government authorities or agencies; and such other risks and uncertainties detailed
in Actavis periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis plcs Quarterly Report on Form 10-Q for the year ended
September 30, 2013 and from time to time in Actavis other investor communications . Except as expressly required by law, Actavis disclaims any intent or obligation to
update these forward-looking statements.
Statements contained in this presentation that refer to Actavis financial results for 2013, including fourth quarter and/or full year 2013 revenues, earnings, tax rates,
margins, profits, and other financial metrics, are preliminary estimates and reflect Actavis expected financial results as of the date of this presentation, and are subject to
change. Such statements are forward-looking statements that reflect Actavis current perspective of existing and information as of the date of this presentation. Actual
results may differ materially from Actavis current estimates and expectations depending upon a number of factors affecting Actavis business. These factors include, among
others, the inherent uncertainty associated with financial estimates and preliminary results; the possibility that financial estimates and results will change after further review
by Actavis management or accountants, or due to discovery of additional or revised information or subsequent events, and other uncertainties detailed in Actavis periodic
public filings with the Securities and Exchange Commission, including but not limited to Actavis plcs Quarterly Report on Form 10-Q for the year ended September 30, 2013
and from time to time in Actavis other investor communications . Except as expressly required by law, Actavis disclaims any intent or obligation to update these forwardlooking statements.
Trademarks noted in this presentation are the property of their respective registered owners.
Paul Bisaro
Chairman and
CEO
Exceptional 2013
Strong commercial performance in high-value markets
Investment in R&D delivering extraordinary results in
Filings/Approvals
Global Operations maximizing cost efficiencies and driving synergy
capture
M&A driving transformation to Specialty Pharmaceuticals
leadership
The Result - Exceptional Financial Performance
Double-Digit Earnings Growth
Exceptional Cash Flow
Significant 1 Year Progress Against Objective
2013-2018
Strategic Objective
Make Actavis a premier global
specialty pharmaceutical
company continuously
delivering sustainable, longterm growth across all
components of our diversified
strategy.
Created Top 20 global pharmaceutical

company by sales
Leadership in Womens Health
Stronger in Urology
Expanded Specialty portfolio
Gastroenterology and Dermatology
Substantial operational synergies coupled

with tax savings from new corporate
structure
Focus on 2014 - Pillars of Growth
Commercial Strength Maximize value of current business

assets to grow revenue and profit
Organic Growth Invest in focused Gx, Rx, Biosimilar R&D;

deliver the pipeline
Operational Excellence Focus on quality, efficiency, synergy

capture and cost control
Business Development Define opportunities that enhance

growth potential execute strategic transactions
New Leadership Structure
PAUL BISARO
Chairman and CEO
SIGGI OLAFSSON
President, Actavis
Pharma
FRED WILKINSON
President, Global
Research & Development
BOB STEWART
President, Global
Operations
New Leadership Structure and Functions

PAUL BISARO
Chairman and CEO
SIGGI OLAFSSON
President, Actavis
Pharma
FRED WILKINSON
President, Global
Research & Development
Global Commercial Sales

Generics
Brands
Branded-Generics
OTCs
Medis
Global Business Development
& Portfolio Management
Global R&D
Generics
Brands
Inhalation
Biologics/Biosimilars
R&D and Business Dev
Global Regulatory Affairs
Global Pharmacovigilance
BOB STEWART
President, Global
Operations
Global Quality
Global Manufacturing, Supply
Chain, Distribution
Global Human Resources
Global Security, IT
Global Ops Excellence
Global Integration Support
Anda Distribution
Aligning Management to Support Pillars of Growth

Redefining Commercial Structure to Focus on Delivering Integrated
Pharmaceuticals Portfolio Globally
Combining Commercial Generics, Brands, Branded Generics, OTCs, Biologics
sales
Redefining R&D Structure to Capitalize on Capabilities while Maintaining

Differentiated Development Teams
Capitalizing on and Efficiencies in Global R&D, Regulatory Affairs, Clinical
Operations, Pharmacovigilance
Redefining Responsibility of Global Operations Organization

Capitalize on expertise and proven track record in cost containment, synergy
capture, integration management
Enhance utilization of human resources and capabilities and capital investments
to build industry leading specialty pharmaceutical company
2014 Segment & Revenue Reporting Structure
ACTAVIS
PLC
SEGMENTS
North American
Gx
ACTAVIS
PHARMA
North American
Rx*
ANDA
Distribution
International
Rx/Gx/OTC/Third-Party
REPORTING UNITS
* Reporting in each category:

Women's Health, Urology/Gastroenterology, Dermatology/Established Brands
Agenda
Actavis Pharma
Siggi Olafsson, President
Global Research and Development
Fred Wilkinson, President
Global Operations
Bob Stewart, President
Global Finance
Todd Joyce, Chief Financial Officer
2014 Forecast and Beyond
Paul Bisaro, Chairman and CEO
Actavis Pharma
Siggi Olafsson
President
Agenda: Actavis Pharma
Global Organization 2013 Highlights

Global Commercial Highlights
ACTAVIS
PHARMA
Commercial Structure
North American Specialty Brands

North American Generics
North American Gx
International
Medis Third-Party
2014 Objectives and Outlook
North American Rx
International
Actavis Commercial Organization Structure
Siggi Olafsson
Commercial
Operations
Global BD
Canada &
LATAM
International
U.S.
UK &
Ireland
N-Europe
MEGT
Russia, CIS
& Ukraine
Central
Europe
SE-Europe
APACA
Womens
Health
International
Medis ThirdParty
Specialty Brands
Womens Health
Urology/GI
Canada
Strategic Marketing
& Health Economics
Dermatology &
Established Brands
Business Operations
Specialty Commercial Structure Maximizes Growth Potential

A global pharmaceutical
company marketing brands,
branded generics, generics, and
OTC products
Many markets are hybrids of Rx, Gx,

and Branded Generics
Common commercial platform

outside of U.S.
Synergies exist in the support

functions distribution, customer
service, contracting
Rx segment will continue to grow as

we bring differentiated products to
our customers
Hx
International
25%
11%
OTC
Specialty N.A.
37%
16%
30%
36%
Generics N.A.
* Proforma Sales with full year Warner Chilcott, excludes Western European
markets to be divested, Medis excluded from channel split
45%
2013*
Gx
Rx
Actavis and Warner Chilcott Integrations
Complete
US Commercial
International Commercial
R&D
G&A / Shared services
Ongoing
Supply Chain
Exceptional Execution
Integration Essentially Complete
2013 Significant Accomplishments

Strong performance across all business segments
-
Specialty brands showed growth in all key promoted products in U.S. & Canada;
successful new launch in Canada of Fibristal
Strong growth in U.S. generics holding #1 or #2 market positions throughout the

year
UK, Russia and the Nordics had an exceptional year showing growth across all
product categories, brands, branded generics, generics and OTC
Optimized International commercial structure and regional focus for future

growth
Impressive execution in R&D this year, expanding robust pipeline for the
future
Foundation for Global Specialty Pharma
Generics and Specialty Brands
Generics and OTC
Brands
Third-party business (alone)
North American
Specialty
Brands
North American Specialty Brands 2013 Overview

2013 Specialty Brands
Net Revenue ($ millions)
$635+
WC
Actavis
$131
$145
$154
Q1
Q2
Q3
Actavis:
Growth in key promoted products:
Generess Fe, Rapaflo, Crinone
and Androderm
Warner Chilcott:
Delzicol launched in March 2013
Minastrin and Lo Loestrin are the
largest franchises of promoted oral
contraceptives
Five product approvals and three
new product launches in 2013
Q4*
* Q4 Data is based on preliminary results
North American Specialty Brands
Significant Potential New Product Opportunities From Existing Pipeline

2013
Oxytrol OTC
Fibristal (CA)
Minastrin 24 Fe
Doryx 200mg
Delzicol
Rapaflo (Brazil)
2014
LoLoestrin (CA)
Levosert (Int)
Diafert (Int)
Metronidazole
Trelstar (CA)
Crinone NG
NG = Next Generation
2015
Udenafil ED
Mesalamine NG
Levosert (US, CA)
Diafert (US)
ella (CA)
Generess Fe (CA)
Doryx NG
2016+
rFSH
Bx Herceptin
Bx Avastin
Bx Erbitux
Bx Rituxan
Udenafil BPH + ED
Esmya (US)
E4/Progestin OC
Sarecycline
Albaconazole
Specialty Brands Expansion Further Diversifies Actavis

Actavis Specialty Sales
North America
~ $2.5 B
Actavis Specialty Contribution

Global Pharmaceuticals
100%
100%
18%
~40%
ACT Specialty
$1.1 B*
ACT Pharma
2013
2014
Est.
* Includes 4th Quarter Sales of Warner Chilcott
2013
2014
Est.
Specialty Brands Highlights

MAY
AUGUST
Acquired Rights To
Metronidazole 1.3%
Vaginal Gel
Acquired
Albaconazole
Antifungal Agent
JANUARY
JUNE
OCTOBER
Acquired Uteron
Pharmaceuticals
Acquired US Rights
to Levosert
Acquired Warner
Chilcott
2013
FEBRUARY
MARCH
APRIL
JULY
Approval of
Delzicol
Launched
Delzicol
Approval of
Doryx 200mg and
Minastrin 24 Fe
Launch of
Doryx 200mg and
Minastrin 24 Fe
Strong Portfolio of US Marketed Products
WOMENS HEALTH
URO
GI
*
*Co-promoted
DERMATOLOGY
U.S. Sales Force
WOMENS HEALTH
UROLOGY
GASTROENTEROLOGY
DERMATOLOGY
~300
150
95
65
Representatives
Representatives
Representatives
Representatives
Strategic Account Specialists:
~55 Reps
Total U.S. Sales Force: 750
2013 N.A. Specialty Sales by Franchise
2013 N.A. Specialty Proforma*

Womens Health
Urology/GI
Dermatology and
Established Brands
* Based on Proforma Sales for Warner Chilcott
CONTRACEPTIVES: $600+ Million Franchise in the U.S.
Moderate Growth
expected in 2014
Bayer
+5%
Teva J&J
5%
1%
4%
90% share of
voice for OCs in
OB/GYN90%
office
Generess Fe
Lo Loestrin Fe
Minastrin 24 Fe
Actavis
Loestrin 24 Fe
2013
Source: IMS Health
2014
WOMENS HEALTH
URO
GI
DERM
ESTABLISHED
Share of Promoted Oral Contraceptives is growing

and Sales Remain Strong
120
100
Lo Loestrin Fe
Minastrin Fe
Generess Fe
Loestrin Fe
Ortho Tri-cyclen Lo
Beyaz
80
60
40
20
0
2013 Weekly TRx
Source: IMS Health Weekly TRx
WOMENS HEALTH
URO
GI
DERM
ESTABLISHED
Leading portfolio in Womens Health includes leading infertility and

hormone replacement products.
2.5
#1 Prescribed HRT for new patients

by OB/GYNs
Crinone
2.0
1.5
+9%
Endometrin
1.0
0.5
0.0
2013 Weekly TRx
2013
2014
2013
2014
WOMENS HEALTH
URO
GI
Continue to Grow Rapaflo

TRx in a stable market
70
Rapaflo
60
50
150
40
100
30
Androderm
2.5 & 5.0 mg
Androderm
2.0 & 4.0 mg
20
50
10
0
4Q11
ESTABLISHED
Successful conversion of
Androderm to improved strengths
250
200
DERM
0
2Q12
4Q12
2Q13
4Q13
Source: IMS Health NPA Quarterly and Weekly TRx Data
4Q09
4Q10
4Q11
4Q12
4Q13
31
WOMENS HEALTH
URO
Mesalamine franchise
is stabilizing
35
Some share lost during

Asacol discontinuation
Sales decline
expected in 2014
-18%
20
Total Mesalamine
franchise
Asacol HD
15
10
Delzicol
Asacol
HD
Delzicol
10
ESTABLISHED
Asacol
25
15
DERM
25
30
20
GI
Asacol
2013 Weekly TRx
2013 Weekly TRx
2013
2014
32
WOMENS HEALTH
URO
GI
DERM
ESTABLISHED
Doryx TRx (Jan 2012 Dec 2013, 000 TRx)
Doryx 150mg
Doryx 200mg
Gx 150mg
70
60
50
Dermatology Highlights
Successful Launch of Doryx
200mg in 2013
40
Slow erosion of Doryx

150mg after Gx entry
30
20
10
0
2Q12
4Q12
2Q13
4Q13
33
Combined Specialty Brands Franchise
Maximize Profits, Select Promotion on Key Products

Established Products
Actonel
Kadian
InFed
Alora
Brevicon
ella
Estrace tablets
Femring
Norinyl
Tri-Norinyl
Oxytrol
Gelnique
Sodium Ferric Gluconate
Actigall
Condylox
Fioricet
Fiorinal
Norco
Sarafem
Estrostep
Ovcon
Microzide
Femcon Fe
FemHRT
Nor-QD
PapSure
PreQue
Actavis Specialty Brands Success Story: CANADA

Growth strategy emerging with notable filings and launches
2014 Lo Loestrin Approval;

Expect Early 2014 Launch
Successful launch of Fibristal

Generess Fe and ella filed
Launched Urology Portfolio

Built Commercial Team
10 products and 60 sales representatives

3 New Product Launches in 2 Years
2 Re-Launches in 2 Years
Revenue from 0 to ~$90M in 3 Years
Significant Scale Acquired

Asacol & Actonel
Robust Portfolio of
Products in Pipeline
Achieved critical
scale and
profitability
North American
Generics
U.S. Generics 2013**

1Q 2013
3Q 2013
2Q 2013
1,135
930
920
895
733
Actavis
Teva
970
718
696
Mylan* Sandoz
943
Actavis
* Sales for North America, U.S. Not Reported
Teva
707
670
Mylan* Sandoz
Actavis
** Based on Public Company Filings
Teva
718
Mylan* Sandoz
North American Generics 2013 Highlights

Key Product Launches
Gx Lidoderm
Lidocaine Patch
Exclusive
Gx Cymbalta
Duloxetine DR
Capsules
Shared Exclusive
Gx Zovirax
Acyclovir Cream
Limited players
Gx Suboxone
Buprenorphine +
Naloxone Sublingual
Tablets
Limited players
>$500 million revenue from U.S. Generic launches in 2013

Key FTF Launch Opportunities and 30 Month Stay Expirations
(Green Date Certain Launches)
2014
Gx Testim
Gx EpiDuo
Gx Daytrana
Gx Gralise
Gx Xopenex HFA
Gx Exjade
Gx Exelon Patch
Gx Celebrex
Gx Micardis
Gx Lialda
Gx OxyContin
Gx Intuniv
2015
Gx Zipsor
Gx Beyaz
Gx Safryal
Gx Fortesta
Gx AndroGel 1%
Gx Namenda
Gx Ortho Tri-Cyclen Lo
2016+
Gx Suboxone Film
Gx Acanya
Gx NuvaRing
Gx Absorica
Gx Axiron
Gx Nucynta IR/ER
Gx Crestor
Gx Ziana
Gx Azilect
Gx Zyclara
Durable Portfolio
5-Year Sales Benchmark
% of Sales
100
Top 40
Top 30
Top 10
Top 20
80
60
40
20
0
1/2009
1/2010
1/2011
1/2012
Source: IMS Data 2009 2013 3-month periods
1/2013
1/2014
Top U.S. products 5 years

ago still retain the
majority of their value
today
The right generic

products can maintain
significant value or even
grow long-term
Top 7 US Buying Entities are ~85% of Gx Market

CVS/Caremark/
Cardinal
Other
Anda
Trends to Note
Global consolidation
among buyers
Rite Aid
Formation of purchase
alliance groups
Walmart
Walgreen/
ABC
McKesson
Econdisc
Large global generic

players best positioned
Canada Generics
2013 Net Revenues $128M
8 products launched in 2013
20 Rx product submissions in 2013
Building OTC Portfolio

Increased Patent Challenge Activity,
including Injectable
Supply chain management improvement
Focus on portfolio diversification
McKesson Award for service excellence
International
Actavis Pharma International
No 1
Bulgaria,
Iceland, Malta,
Mongolia,
Singapore,
Sweden
Top 3
Denmark,
Greece, Hong
Kong, New
Zealand,
Norway, Serbia
UK
Top 5
Australia,
Austria, Estonia,
Finland, Ireland,
Lithuania
Top 10
Czech,Hungary
Latvia, Romania,
Russia,
Switzerland,
Ukraine
Redefined International Focus Markets

Examples
Strong, profitable
lead markets
Growth
Opportunities
Optimize
Reduced focus/
Out-license
countries
Russia
UK
Nordics
Japan
Brazil/Mexico
South-East Asia
Middle East
Australia
Greece
France
Germany
Italy
Spain
Focusing internal
resources and
investments to optimize
value and growth
Diverse Platform for Future Growth

International
Channel Split by 2013 Sales*
Hospital
Opportunities for growth

across all channels
11%
OTC
37%
16%
36%
Rx
Investing in Sales &

Marketing to grow Rx and
OTC segments
Leveraging pipeline across
multiple regions
Gx
*Excludes Third Party and recently announced Western European divestiture markets
Initiated a Shift in Western European Markets

Signed Term Sheet to Divest Businesses
to Aurobindo
Actavis retains:
Closing expected in March

Select generic commercial operations:
France, Germany, Italy, Spain, Portugal,
Netherlands & Belgium
Estimated 2013 revenues of $466M
Transfer of related commercial

infrastructure, products, pipeline
Conditional on certain antitrust approvals
and completion of employee consultation
processes.
The Third-Party
business
(Medis/Specifar) and
manufacturing plants
The freedom to
operate in the
Specialty Branded and
biosimilars business
Europe
2013 Net Revenues $1.4B
Strong #4 Market Position
458 Product Launches, 313 Submissions
Major product launches on target
Strong Cluster Performance

Outstanding contribution:
2013 Revenue Breakdown**
UK/Ireland taking advantage of shortages.

Strong performance of Rx segment and OTC
Russia strong performance in Rx segment
and OTC
Central Europe strong growth in revenue and
contribution
Nordics capitalizing on strong market position
*Based on preliminary results. Excludes recently announced divestiture of Western European
markets. Includes Warner Chilcott for the fourth quarter of 2013.
** Data based on Actavis Pharma only
MEGT (Middle East, Greece and Turkey)

2013 Net Revenues: $125M*
30 Launches, 17 Submissions
Strengthened Regional office in Dubai
Largest Markets: Turkey, Greece and Saudi Arabia

7% 2013
Strong potential for growth in specialty 9%

franchises
Strong focus on building portfolio
Turnaround in Turkey
7%
Branded Gx markets
11%
Turkey
7%
7%
Turkey
Greece
36%
36%
9%
Greece
Saudi
Arabia
Saudi Arabia
Iraq
Iraq
11%
Iran
Iran
Other
Greece outperforming market
30%
30%
*Based on preliminary results
Revenue Breakdown
Other
APACA (Asia-Pacific, Africa)

71 Launches, 86 Submissions
Establishing regional office in Singapore
2013 Revenue Breakdown

Focus on strengthening portfolio
Strong performance of New Zealand,
Vietnam, Hong Kong and Malaysia
Australian business consolidated as Actavis

Redefining S&M strategy in Indonesia
Divested business in China
5%
5%
6%
6%
PacificPacific
(AUS & NZ)
6%
6%
Asia Asia
Indonesia
Indonesia
10%
10%
51%
51%
South South
Africa Africa
North North
Africa Africa
22%
22%
Japan
Japan
LatAm
Mostly Brazil
Smaller contributions from Mexico and Colombia
7 Product Launches, 18 Submissions
Approval of Rapaflo in Brazil
Strengthened sales force in Brazil

Established Actavis Mexico
Entrance with oncology in Colombia
Pending Market Authorizations end 2013:
12 in Mexico,
22 in Brazil and
8 in other countries in the region
OTC
New Products, Line Extensions, New Territories
Russia and Ukraine
Blockbusters
Troxevasin and Spasmalgon line
extensions
Entered allergy segment in Russia
Dental Range
iWhite in Sweden and Norway
new territories in making
Launch of Oralflux in Czech
and Poland
Preparing Flux launch in
Greece, Slovakia and Serbia
Decubal
Launched in Greece in 2013
Preparing launch in ME
Lactocare
Launched in Finland and Norway
Preparing launch in Greece and in
Turkey under ProBac brand name
Future Product Opportunities

Market
Opportunity
Capabilities
Center of Excellence London
Inhalation
Injectables
Ophthalmics
& Otics
$37+ Billion
global market
Limited Generics
$20+ Billion
global Generic market
Many new Rx targets
$13+ Billion
global market
Limited Generics
Dedicated leadership,
expanding team
Partnerships for devices and
manufacturing
Strong capabilities in R&D,
(cytotoxic, pre-filled syringes)
Two injectable manufacturing

plants FDA inspected
Partnerships established for
complex technologies
Strategic global partner
and co-development
Selective licensing based
on timelines and product
Development
Targeting products covering
>50% of global market;
- MDIs and DPI
- Nasal Sprays
Robust pipeline of more than 50
products
- 505(b)(2) NDAs
- Complex injectables
- Strong oncology focus
Targeting all dosage forms;
- Suspensions
- Solutions
- Gels and ointments
International Specialty Brands
Mesalamine
Franchise
Focus on UK
Product
continues to
grow
Opportunity to
expand into
selective
markets
Womens Health
Building portfolio
throughout the region
OCs
Progesterone
Cacit
Tests
New Launches
Levosert
Diafert
Medis Third-Party
2013 Highlights
Integration of Medis, Specifar, Breath and
Spirit complete one unified business
215 new agreements signed in 2013 (highest
number ever achieved)
Record 215 new agreements

signed on 103 products with 91
companies
215
200
189
50 contract extensions (prolongations)

Diverse Customer base
-
211 active customers covering the full range from

top Gx players to small local start-ups
Global coverage of 130 countries
129
Progressing with expansion into new emerging

markets
2010
2011
2012
2013
Looking Ahead: 2014 Specialty Brands
Womens Health
Appropriately
position portfolio of
OCs to drive growth
Focus on Lo
Loestrin &
Minastrin
Accelerate growth of
Estrace Cream
Uro /GI
Rapaflo
Grow GI franchise
and enhance market
access position
Maximize opportunity
for Delzicol in
Ulcerative Colitis
Expand portfolio
Derm / Established
Brands
Capitalize on Womens Health product launches in

Canada, including Fibristal and LoLo
Doryx 200mg
Opportunistic
marketing of select
established brands
Looking Ahead: North American Generics

No change in strategy - stay the course and execute
- Maintain U.S. market as a key focus for the
organization
- Continue focus on developing complex, high barrier
products and patent challenges
- Grow Canada portfolio with differentiated product
offering
Looking Ahead: International

Specialty
Launch Diafert and Levosert
Emerging leadership in Womens Health
Europe and Eastern Europe
Expand sales force in key markets
Expand portfolio
Improved on already strong market position
APACA & MEGT
Expand portfolio
Business development opportunities to increase scale
Expand geographically within region
2014 Outlook
2014 Forecast
Net Revenues
North American Brands
Womens Health
~$8.7B
$2.4B - $2.5B
$1.0B - $1.1B
Urology / Gastroenterology
$850M - $900M
Dermatology / Established Brand
$500M - $550M
$3.9B - $4.0B
International Revenue
$2.2B - $2.3B
* Excludes recently announced divestiture of European Markets. Refer to tables at end of presentation for a reconciliation
of non-GAAP items.
Global R&D
Fred Wilkinson
President
Agenda: R&D
Organization and Capabilities

Generic R&D Update
Global Specialty R&D Update
Biosimilars R&D Update

2014 Objectives
Actavis R&D Organization Structure

Actavis R&D
Fred Wilkinson
Inhalation
Gx Development
Generic
Gx Clinical
Pharmacovigilence
Gx Regulatory
Gx Proj Mgt
Global PM
Solid Oral
Dosage
Internal Gx
(India)
International Gx
Semi-Solid &
Liquid
Internal Gx
(Florida)
US Gx Regulatory
Hospital/
Injectables
External Gx
API
Specialty
Brands
Biosimilars
Wom Health &

Medical Affairs
Develop &
Manufacturing
Urology/GI
Dermatology
Scientific
Officer
Brand
Regulatory
Project
Management
Biosimilar
Strategic Planning
Powerful Global R&D Combination
Combining generic, specialty, inhalation and biosimilar R&D

Development will remain separate for each category
Generic R&D will focus on Generics
Brand R&D will focus on Brands
Biologics R&D will focus on Biosimilars
Maintain commercial input from business areas

Coordinate and streamline R&D support functions to increase
efficiency
Regulatory
Pharmacovigilance
Elimination of duplicate processes allows savings to be reinvested

Collaboration between teams adds powerful advantage and will
enhance success
Global R&D Network

IR Oral Solids
India
Iceland
Larne, Northern Ireland
Belgium
MR Oral Solids
Florida, USA
New Jersey, USA
Bulgaria
Hafnarfjordur Iceland
Patch/Topicals
Utah, USA
Maryland, USA
Bulgaria
Dundalk Ireland
Injectables
Italy
Romania
Larne Northern Ireland

Liege Belgium
Elizabeth, NJ USA
North Brunswick, NJ USA
Bucharest Romania
Troyan Bulgaria
Owings Mills, MD USA

London UK
Liverpool UK
Salt Lake City, UT USA
Bangalore India
Others
Lotus BE and CE
studies, India
CRO in Miramar, FL
Inhalation/new
technologies, UK,
North Brunswick, NJ
Indonesia (Local R&D)
API development,
India
IUD, Clinical,
Regulatory, Liege,
Belgium
Chennai India
Jakarta Indonesia
Weston, FL USA
Miramar, FL USA
Nerviano Italy
Navi, Mumbai India
Ambernath India
Clinical Ops
Utah, USA
NJ, USA
Larne, Northern
Ireland
Belgium
Commitment to Organic Growth through R&D*

Internal development by year, in millions
29%
14%
57%
* 2013 Includes one quarter Warner Chilcott; Based on Preliminary Results
Generic R&D
Realizing Value of Watson/Actavis Combination*
25%+ capacity for

additional projects
Consolidation
of overlap
~50%
Overlap
Non-Overlap
Actavis
2012
Watson
2012
*Illustrative Purposes Only
2013+
Synergies capture
results in increased
number of projects
2013 Generic R&D Performance

New Dossiers/ANDAs by Year
2013 Highlights
~240
Japan
Australia
Russia
153
Other
EU
CA/
LatAm
111
.U.S.
2012 *
2013
* Proforma for Watson and Actavis
2014
Opportunties
Delivered filings across all dosage forms

and regions
Expanded in-house capabilities
- Clinical site in the U.S.
- Inhalation team in London
Reinvesting savings from R&D
efficiencies into new complex products
Robust filing plan for 2014, we have
more opportunities to work on than ever
Actavis the Leader in U.S. First-to-files

Confirmed First-to-File # Products in 2013 by Company
18
Exclusive FTF
Shared FTF
12
10
3
6
2
6
5
1
5
1
7
4
4
1
4
1
Actavis Sandoz Mylan Amneal Apotex Hetero Glenmark Zydus
3
1
2
Teva
Roxane Alkem
Labs
Source: FDA website, Public lawsuits, Internal Analysis

Note: Total is greater than 44 due to shared FTFs, FTF company not identified for 6 products
Lupin
Dr.
Others
Reddys (14)
Achieved Significant Share of FTFs in 2013

First-to-File # Products in 20131
Product Sales of FTFs in 20132 ($ in billions)
Exclusive
Shared
$2.1
26
44
Exclusive
Shared
64%
41%
$5.8
$2.7
12
$1.0
6
Total
1
2
Others
Actavis
First-to-Files posted on the FDA website in 2013

IMS Health Sales MAT Nov. 2013
Total
Others
Actavis
PIV Filings Strengthen U.S. Pipeline

Product
Dosage Form
Status
30-Month Stay
Gx Testim
Topical Gel
Limited Filers
2014
Gx Epiduo
Topical Gel
Actavis FTF
2014
Gx Daytrana
Transdermal
Actavis FTF
2014
Modified Release Tablets
Actavis FTF
2014
Metered Dose Inhaler
Actavis FTF
2014
Capsules
Actavis FTF
2014
Gx Exelon
Transdermal
Actavis FTF
2014
Gx Exjade
Immediate Release Tablets
Actavis FTF
2014
Gx Zipsor
Soft Gel Capsules
Actavis FTF
2015
Gx Beyaz
Oral Contraceptive
Actavis FTF
2015
GX Safyral
Oral Contraceptive
Actavis FTF
2015
Gx Fortesta
Topical Gel
Actavis FTF
2015
Sublingual Thin Film
Actavis FTF
2016
Topical Gel
Actavis FTF
2016
Gx Nuvaring
Vaginal Ring
Actavis FTF
2016
Gx Absorica
Capsules
Actavis FTF
2016
Topical Solution
Actavis FTF
2016
Gx Nucynta IR
Immediate Release Tablets
Actavis shared FTF
2016
Gx Nucynta ER
Modified Release Tablets
Actavis shared FTF
2016
Gx Gralise
Gx Xopenex HFA
Gx Revlimid
Gx Suboxone Film
Gx Acanya
Gx Axiron
Yellow = 2013 additions to disclosed pipeline, does not include all filings
53 new U.S.
filings submitted
in 2013
Approx. 70%
included PIV
patent
challenges
20+ additional
potential FTFs
waiting for
acceptance by
FDA
Actavis U.S. Pharma Pipeline Select Categories

Development
Filed
Approved /
Launched
Inhalation
6 active projects, including;

- Meter Dose Inhalers
- Dry Powder Inhalers
- Additional International
projects underway
Xopenex HFA MDI

Nasal Spray
Various nebules
Injectables
More than 30 active projects

including;
- 505(b)(2) NDAs
- Complex injectables
- Strong oncology focus
15 products
16 products (most via

market partner)
Ophthalmics
& Otics
8 active projects, including;

- Suspensions
- Solutions
- Gels and ointments
17 products
Launching 2014+
Significant Expansion of Internal Clinical Study Capabilities

Internal vs. External Studies
~15%
Acquired 160 bed CRO in
Florida in mid-2013
65%
600 beds in 5 locations in

India and 1 location in
Florida
Current Capacity: ~400
studies per year
Internal External
2012
Total
Internal External
Total
2014 Est
Specialty R&D
Specialty Brands R&D 2013 Achievements
APPROVALS
REGULATORY FILINGS
Oxytrol for Women in US

Fibristal (single cycle) in Canada
Crinone New Applicator in US
Rapaflo in Brazil
Trelstar 6 month in Canada
Levosert (Menorrhagia) in UK & 12
Central Eastern European countries
LoLoestrin in Canada
Progestin only patch

Fibristal (multi-cycle) in Canada
ella in Canada
Levosert (Contraception) in UK & 12
Central Eastern European countries
Levosert (Contraception & Menorrhagia)
in UK & +15 EU countries
Generess Fe in Canada
Rationalized Actavis Specialty Pipeline

Preclinical
Phase 1
Colvir HPV
Esmya Vaginal Ring

Vaginate BV
Phase 2
Albaconazole
VVC
Rapaflo NextGen
WC3037
E2 Vaginal Capsules
WC3058
Etonogestrel Ring
WC3081
1mg NA/20 ug EE
Softgels
Phase 3
Esmya-Fibroids
(US)
Metronidazole 1.3%
Vaginal Gel
Diafert
Levosert
Contraception
E4/Progestin OC
WC3079
Delzicol NextGen
WC3046
Delzicol 800mg
WC3011
E2 Vaginal Cream
WC3055
Udenafil BPH
WC3035
Sarecycline
WC3065
1mg NA/10 ug EE
Softgels
WC2055
Doxycycline NextGen
Amg/Act Rituxan
Oxybutynin
Hyperhidrosis
Amg/Act Erbitux
Albaconazole
Onychomycosis
MAA
WC3043
Udenafil ED
Amg/Act
Herceptin
Amg/Act
Avastin
Approved
Fibristal
Canada
Progesterone
Vaginal Gel
Oxytrol OTC (Merck)
Progestin Only Patch
Levosert HUB
UK/EE
WC3040
1mg NA/20 ug EE
Chewable Tablet
WC3064
1mg NA/10 + 10 ug EE
Chewable Tablet
Rapaflo Brazil
rFSH
Rapaflo Canada
Delzicol 400mg
Womens Health
Urology
GI
Contraceptives
Biologic
Dermatology
Doryx 200mg
Womens Health Franchise: Select Portfolio + Pipeline

Levosert (levonorgestrel-releasing IUD)
Indication
Levosert
Contraception
Diafert
Regulatory &
Estimated
Launch
Esmya/Fibristal
E4/ Progestin
OC
WOMENS
HEALTH
Menorrhagia & Contraception
Competition
Market Value
U.S.: NDA expected to be filed

2014
ROW: Approved for menorrhagia
in UK and 12 Countries in CEE &
Launching in 2014;
Contraception submitted in EU
CAN: NDS expected to be filed
2014
U.S.: Mirena/Skyla,
Paragard, Nexplanon
ROW: Mirena/Skyla & non-drug
loaded IUDs
U.S. Market: $890 million (IMS Health)
ROW Market: $406 million + (IMS
Health-MIDAS)
Diafert (non invasive adjunctive IVF selection assay)
Levosert
Contraception
Indication
Diafert
Esmya/Fibristal
E4/ Progestin
OC
WOMENS
HEALTH
Improve embryo selection in IVF

U.S.: 510K expected to be filed
2014
ROW: CE Mark in 2014
CAN: Class II Medical Device
submission 2014
Regulatory &
Estimated
Launch
Competition
No direct competitor
Market Value
U.S.: 154,412 IVF Cycles (SART 2011)

ROW: 877,330 IVF Cycles (ESHRE
2010)

Esmya (Ulipristal Acetate tablets)
Indication
Levosert
Contraception
Diafert
Regulatory &
Estimated
Launch
Esmya/Fibristal
Esmya/Fibristal
E4/ Progestin
OC
WOMENS
HEALTH
Treatment of signs and symptoms of

uterine fibroids
U.S.: Phase 3 uterine-sparing
clinical initiated; NDA expected to
be filed 2016
ROW: Approved & Launched by
GR
CAN: Approved in women eligible
for surgery & Launched in 2013
Competition
Leuprolide for preoperative

hematologic improvements of anemia
caused by uterine fibroids
Market Value
First in class indication potential

millions of women treated annually for
fibroids; >$500* million in U.S. & CAN
*Based on 300,000 hysterectomies annually in

U.S. and CAN
E4 (Estetrol combination Oral Contraception)
Levosert
Contraception
Indication
Diafert
Regulatory &
Estimated
Launch
Esmya/Fibristal
Competition
E4/ Progestin
OC
WOMENS
HEALTH
Oral Contraception
Market
Potential
U.S.: Initiating Phase 3 in 2014

ROW: Initiating Phase 3 in 2014
U.S.: Combination OCs

ROW: Combination OCs
U.S.: $3.6 billion (IMS Health)

ROW: $4.5 billion (IMS Health)
URO / GI Franchise: Select Portfolio + Pipeline

WC3043 (Udenafil tablets)
WC3043
Udenafil ED
Indication
WC3055
Udenafil BPH + ED
WC3046
Delzicol 800mg
Erectile Dysfunction
Regulatory &
Estimated
Launch
Competition
U.S.: NDA expected to be filed

2014 & Launch in 2015
2014 & Launch in 2015
U.S.: Viagra, Cialis, Levitra,

Stendra
Market Value U.S.: $2.5 billion
WC3079
Mesalamine NextGen
URO / GI

WC3055 (Udenafil tablets)
WC3043
Udenafil ED
Indication
WC3055
Udenafil BPH + ED
WC3046
Delzicol 800mg
BPH + Erectile Dysfunction
Regulatory &
Estimated
Launch
Competition
U.S.: Initiate Phase 3 in 2014;

NDA expected to be filed 2016
2016
U.S.: Cialis
Market Value U.S.: $1.2 billion
WC3079
URO / GI
Mesalamine NextGen

WC3046 (Delzicol 800mg)
WC3043
Udenafil ED
Indication
WC3055
Udenafil BPH + ED
WC3046
Delzicol 800mg
WC3079
URO / GI
Mesalamine NextGen
Ulcerative colitis
Regulatory &
U.S.: sNDA expected to be filed
Estimated
2015 & Launch in 2015
Launch
Competition
Lialda, Pentasa, Rowasa,

Apriso
Market
Potential
$1.9 billion (IMS Health)

WC3079 (Mesalamine NG)
WC3043
Udenafil ED
Indication
WC3055
Udenafil BPH + ED
WC3046
Delzicol 800mg
WC3079
URO / GI
Mesalamine NextGen
Ulcerative colitis & maintenance of

remission
Regulatory &
U.S.: NDA expected to be filed 2014
Estimated
& Launch in 2015
Launch
Competition
Lialda, Pentasa, Rowasa,

Apriso
Market
Potential
$1.9 billion (IMS Health)
Dermatology Franchise: Select Portfolio + Pipeline

WC2055 (Doxycycline NG)
Indication
WC2055
Regulatory &
Estimated
U.S.: NDA expected to be filed 2014
Launch
Competition
Oral doxycycline & minocycline

(Solodyn, Monodox, Oracea,
Minocin)
Market
Potential
$1.2 billion in brand value
Doxycycline NextGen
WC3035
Sarecycline
DERM
Doxycycline class labeling, including

acne
(IMS Health)
Dermatology Franchise: Select Portfolio + Pipeline

WC3035 (Sarecycline)
Indication
WC2055
Regulatory &
Estimated
U.S.: Entering Phase 3 in 2014
Launch
Competition
Oral doxycycline & minocycline

(Solodyn, Monodox, Oracea,
Minocin)
Market
Potential
$1.2 billion in brand value (IMS Health)
Doxycycline NextGen
WC3035
Sarecycline
DERM
Moderate to severe acne
Biosimilar R&D
Biosimilar Franchise: Select Portfolio + Pipeline

rFSH (follitropin alpha)
rFSH
Indication
Amg/Act
Rituxan
Amg/Act
Erbitux
Amg/Act
Herceptin
BIOLOGICS
Amg/Act
Avastin
Development of multiple follicles in

ART program (IVF)
Regulatory &
ROW & U.S.: Initiated Phase 3 in 4Q
Estimated
2013
Launch
Competition
Gonal-F, Folistim, Menopur,

Bravelle
Potential
Value
U.S.: $450 million (IMS Health)

ROW: $1,035 million (IMS Health)
Oncology Biosimilar Programs Progressing to Plan
ABP 215: Bevacizumab (Avastin)

Developed entirely at Amgen
Principal similarity assessment complete
Phase 1 study successfully completed
Pivotal P3 trial has started
ABP 798: Rituximab (Rituxan)

Being developed at Amgen
Final clone selected
Process development in progress
ABP 980: Trastuzumab (Herceptin)

Acquired from Synthon
Tech transfer to Amgen complete
EU P1 successfully completed
Pivotal P3 trial has started
ABP 494: Cetuximab (Erbitux)

Complete Cell Line Development, Actavis
Bob Stewart
President
Global Operations
Global Operations Strategy Simply Stated

1. Supply high-quality products
2. Exceed customer expectations
3. Operate network safely and environmentally
responsible
4. Align operational structure to support end-toend supply chain
5. Continue to maximize Anda capabilities
6. Execute every day
Actavis Global Operations Structure
GLOBAL OPERATIONS
BOB STEWART
Manufacturing
(Americas)
Manufacturing
(ROW)
Global
Engineering
Manufacturing
(Inject)
Information
Technology
Supply Chain
Human
Resources
Operational
Excellence
Quality
Pharmaceutical
Technology
Anda
Distribution
Structure allows for end-to-end supply chain integration
2013 Highlights
Continued transformation to Supply Chain driven
organization
S&OP deployment including 24-month demand forecast
Rationalizing manufacturing network
Lidocaine launch
Integration of Actavis and Warner Chilcott complete
Ongoing rationalization of supply chain
2013 GMP Regulatory Inspections - Summary

47 Regulatory Inspections
FDA
FDA, 11
MHRA/EMA/EDQM
ANVISA
HEALTH CANADA
Other, 23
TGA (Australia)
MHRA / EMA /
EDQM, 6
ANVISA, 3
TGA (Australia), 1
HEALTH CANADA,
1
Other
(AIFA, BDA (Bulgaria), BFSA, DHMA

(+MHRA), Egyptian MOH, SFDA, HSA
(Singapore), MMA, MOH Serbia, NDAMD
(Romania), NOM (Greece), Health Care
Inspectorate and PMDA (Japan)
Global Operations: Manufacturing Capabilities

Manufacturing network ~30 Global Plants
Four New Plants from Warner Chilcott
Manufacturing capacity ~44 Billion Solid Oral Dosage Units
Extensive capabilities in modified release, solid dosage, semi-solids,
transdermals, gels, liquids and injectables
Responsible for producing more than 1,100 generic products and more
than 30 branded products
Capability to produce broad line of products with variety of dosage
technologies
Leveraging Acquired Warner Chilcott Assets

Fajardo, Puerto Rico
Solid Oral Dosage, Tax
Advantages
Manati, Puerto Rico: Solid Oral

Dosage, Tax Advantages
Larne, N Ireland
Devices
Capability
Weiterstadt, Germany
Modified Release
Dundalk, Ireland Stability &
Biologics
Global Supply Chain Optimization
Planned Closures, Sale or

Restructuring
Alathur India
Changzhou City China
Corona, CA USA
Foshan China
Groveport, OH USA
Lincolnton, NC USA
Mississauga, Ontario Canada
Mt. Prospect, IL USA
Podolsk Russia
Zoetermeer The Netherlands
Site Categorization Investment Profile

Rationale
Strategic
Hold
Divest
Investment Profile
Specialized Technology
Low Cost
Portfolio Growth
IP Landscape
High Capital Investment

New Product Registrations
IT Integration
Regional Importance
Cost Profile
Maintenance Capital
New Products
(where makes sense)
No Longer Needed
Redundant Capability
Challenge Headcount
Limited IT Integration
Capital limited to Emergency

No IT Integration
Manage Headcount Decline
Long-Term Manufacturing Strategy Aligned to R&D

Changing demand: Shift from tablets/capsules and
ointments/creams to potent, injectables and special technologies
Changing Finished Dosage Manufacturing Capabilities

Current
Capacity
Type of Mfg.
Growth
Tablets/Capsules
Ointments/Creams
Potent
Injectable
Special Technologies
(ODT, patches)
Investment
Strategy
Rationalize Footprint
Maintain
Invest
Within our
Invest
normal capital
profile
Invest
Relentless Drive for Efficiency

Typical efficiency improvement focus
Manufacturing
Reducing conversion cost (i.e. local lean and OE

initiatives)
Securing manageable plant loads and service levels
Procurement
Improving conditions on API, packaging materials,

excipients
Supply Chain
Quality
Supporting first pass right efforts

Improving quality cost per unit
Engineering
Efficient capacity expansion/allocation programs
Pharm Tech
Improving product transfer/ramp-up cost and times

Improving yields and reducing rejection rates
Optimizing batch sizes
Improving customer service levels

Balancing plant loads
Optimizing inventory levels/turns
Optimizing in-house vs. buy decisions
Product cost
Quality
Service levels
Margin
Improvement
Actavis Integration Engine
Actavis
Integration
Engine
Integration friendly
overall organization
structure
Divisions (Pharma and Specialty Brand) focus on Commercial and R&D

integrations
Operations drives integration of backbone/infrastructure functions
(Manufacturing, SC, Quality, IT, HR)
Dedicated
integration
architecture
Dedicated Integration Office combined with HR oversees and coordinates

all integration activities
Functional line teams responsible for planning/executing functional
integration
Clear targets and

rigorous control
Value creation goals defined before acquisition with clear allocation to

individual teams
Constant monitoring of progress (financial, HR, and content milestones)
with direct reporting into Integration SteerCo
Efficient working
formats and
standards
Standardized working formats across teams

Detailed checklists/playbooks by integration team
Regular cross functional reviews and interdependency checks
2014 Global Operations Priorities

Continue to optimize Supply Network
Drive COGs lower (procurement, conversion, and
distribution)
Shift capital allocation toward new technologies
Capitalize on 2013 investments (IT, Supply Chain, Quality)
Enhance capabilities of global team through best practices in
Human Resources
Drive for excellence in cost containment, efficient utilization
of resources
Anda Overview
Anda, Inc. is the largest distributor within the US competing with the big-3 wholesalers,
with sales exceeding forecast for 2013
Anda purchases and distributes products from 350+

manufacturers, including Actavis, to 60,000 accounts+.
Anda shipped to more than 85% of the pharmacies in the

U.S. in 2013
Andas Divisions
Andas two divisions touch all
trade classes:
Retail
Mail Service
Long Term Care
Specialty Pharmacy
Government
Out-Patient Hospital
Physician
Clinic
In-Patient Hospital
Anda: 2014 Highlights & Growth Drivers

Increased Chain Opportunities Virtual Warehouse
Retail Independents remain a strong segment
Grow AndaMeds
- Physician business growing sales each month after division rebranding
Growth Drivers
Continue to enhance value for large chains
Expand portfolio of products for brands and specialty Be the Primary
Secondary
Anda: 2014 Forecast
Anda Distribution revenue ~$1.5 billion
Adjusted gross margin 11% 13%
Adjusted SG&A 8.5% - 9.5%
Actavis
Financial
Update
Todd Joyce, CFO
Agenda
Achievements and operating trends
Debt trends and capitalization
Revenue diversification and cost trends
Financial reporting changes
Consolidated and segment forecasts
Strong Non-GAAP EPS and Adjusted EBITDA Trends

~33% CAGR
57%+ YOY
*
~34% CAGR
60%+ YOY
*
* 2013 results are preliminary and unaudited and represent the high end of the 2013 forecast range for expected Non-GAAP EPS of $9.26 - $9.39 and Adjusted EBITDA of $2.22 - $2.24 billion provided on October 29, 2013. Reconciliations between
GAAP and Non-GAAP results/expectations can be found in the Actavis October 29, 2013 press release. On January 14, 2014, Actavis disclosed that 2013 results are anticipated to be modestly above this October 29, 2013 Non-GAAP forecast.
2013 Achievements
Strong earnings growth and cash flow generation
Strategically expanded our branded franchise
Seamlessly integrated acquired businesses
Synergies realized as expected
Re-domiciled to Ireland and reduced corporate tax rate
Reduced debt leverage ahead of schedule
Commitment to Organic Growth through R&D*

Internal development by year, in millions
29%
14%
57%
* 2013 Includes one quarter Warner Chilcott; Based on Preliminary Results
Historic Commitment to Rapid Deleveraging
* Preliminary results
** Assumes no additional M&A
Pro-Forma
Leverage
Gross debt
Robust cash flow generation

post-M&A transactions
Delevering Ahead of Schedule

12/31/2013
Capitalization*
Percent
of Total
Leverage
Ratio**
265
1.4%
0.08x
ACT Term Loan
1,310
7.0%
0.40x
WC New Term Loan
1,833
9.8%
0.56x
ACT Notes
4,300
23.0%
1.32x
WC Note
1,250
6.7%
0.38x
94
0.5%
0.03x
9,052
48.5%
2.79x
9,612
51.5%
18,664
100.0%
Cash and Marketable Securities
ACT Revolver
338
Senior Notes
Other
Total Debt
Equity
Total Book Capitalization
* Preliminary. Subject to finalization of 2013 results.

** Leverage ratio based upon last twelve month preliminary pro-forma adjusted EBITDA including Warner Chilcott
Staggered Debt Maturities Provide Flexibility

Projected cash flows and pre-payable debt allows for rapid deleveraging**
2014 Free Cash Flow Estimated between $1.75 - $2.0 Billion
* Company expects to call Warner Chilcott $1.25B 7.75% Senior Notes due 2017 this year
** Excludes impact of M&A
Robust Revenue Growth and Diversification

Significant expansion of brand and international revenues
* Projected. Excludes revenue from recently announced Western European divesture of select commercial markets.
Favorable Non-GAAP Tax Rate Trend
Refer to reconciliation table at end of presentation for a reconciliation of non-GAAP items.
Significant post 14 Cost Reduction Opportunities

OPERATING MARGINS
Further plant and supply chain optimization
Leveraging global commercial capabilities
Procurement savings including API and indirect costs
Further globalization of corporate functions
TAX RATE
M&A structuring through internal leverage

Migration of existing high taxed IP over time
Offshore IP development and new product launches
Selective offshoring of certain activities
2014 Segment & Revenue Reporting Structure

ACTAVIS
PLC
SEGMENTS
North American
Gx
ACTAVIS
PHARMA
North American
Rx*
ANDA
DISTRIBUTION
International
REPORTING UNITS
* Revenue reporting for the following:

Women's Health, Urology/Gastroenterology, and Dermatology/Established Brands
2014 Forecast Key Assumptions

Mid single-digit erosion on U.S. base business
High single-digit price erosion internationally

Additional competition on Gx Lidoderm in Q1 14
Launch of Gx Oxycontin and Gx Intuniv in 2H 14
One additional competitor for Gx Concerta

Mid-year generic competition on Actonel
No further generic competition on other Specialty Brands products
Excludes M&A and business development

Excludes divested operations
2014 Forecast Update
Net Revenues
GAAP R&D
GAAP SG&A
Non-GAAP Tax Rate
Current Forecast
Previous Forecast
~$10+B
~$10B
$800M - $850M
$2,000M - $2,100M
16.5% 17.5%
Adjusted EBITDA*
$3,150 - $3,250M
Non-GAAP EPS*
$12.60 - $13.10
* Refer to tables at end of presentation for a reconciliation of non-GAAP items.
16% 18%
$12.25 - $13.00
2014 Segment Forecast

Segment Revenues, Adjusted Margins, and SG&A% of Revenues
Net Revenues
Adjusted Gross Margin %*
Adjusted SG&A %*
Pharmaceuticals
Anda Distribution
~$8.7B
~$1.5B
63% - 66%
11% - 13%
21.0% - 22.5%
8.5% - 9.5%
* Refer to tables at end of presentation for a reconciliation of non-GAAP items.
2014 Pharmaceuticals Segment Revenue Forecast

Reporting Unit Breakdown
2014 Forecast
Net Revenues
North American Brands
Womens Health
~$8.7B
$2.4B - $2.5B
$1.0B - $1.1B
Urology / Gastroenterology
$850M - $900M
Dermatology / Established Brand
$500M - $550M
$3.9B - $4.0B
International Revenue*
$2.2B - $2.3B
* Excludes recently announced divestiture of European Markets. Refer to tables at end of presentation for a reconciliation of non-GAAP items.
Other Assumptions
INTEREST AND FOREIGN EXCHANGE
Assumes debt paydowns of approximately $2.0 billion
Includes early redemption of $1.25 billion of legacy Warner Chilcott bonds
Key currency exchange rate assumptions:

Currency
FX Rate
in USD
AUD
0.89
CAD
0.95
CHF
1.08
EUR
1.30
GBP
1.54
RUB
0.03
2014 Cash Flow Estimates

2014 Forecast
Operating Cash Flow
$2.0 $2.2 billion
Capital Expenditures
$200 - $250 million
Free Cash Flow*
$1.75 - $2.0 billion
* Cash flow generation sufficient to reduce leverage to 2.2x by year-end
Paul Bisaro
Chairman and
CEO
Driving Long Term Shareholder Value
Global Specialty Industry Realities

Pharmaceutical Industry
Larger / Broader Product Offerings
Converging on Specialty Business Model
Consolidation and M&A

Bolt-ons for scale, commercial footprint, product lines
Synergies a significant driver
Pricing Pressures and Growth in Pharmerging Markets vs Mature

Markets
Consolidation of Customer Base
Duplicating R&D Efforts / Expense in Race for Gold
Two-Prong Commitment to Growth
Double-digit Y-o-Y Organic Earnings Growth

$9.39+
$10.00
38% CAGR
$7.50
$4.77
$5.00
$2.50
$1.37
$2.03
$3.04
$3.42
2009
2010
$6.00
$0.00
2007
2008
2011
2012
Non-GAAP EPS
Strategic M&A / BD to Power Additional Earnings Growth
2013
Focus on 2014 - Pillars of Growth
Commercial Strength Maximize value of current business assets to

grow revenue and profit
Organic Growth Invest in focused Gx, Rx, Biosimilar R&D; deliver the
pipeline
Operational Excellence Focus on quality, efficiency, synergy capture

and cost control
Business Development Pursue opportunities that enhance growth

potential strategic and financially compelling, integrate rapidly
2014 Estimated Free Cash Flow ~$2bn
M&A - Priorities
Geographic Expansion
Supplement Brand Portfolio and Pipeline
Business Growth Plan

Commitment to Long-Term Earnings Growth
2014*
2015
2016
2017
35%+
10%+
10%+
10%+
NA Gx/ International
Pharma Principal Growth
Driver
-Specialty Brands Adding
Additional Value
Increasing Contribution of
Specialty Brands
Introduction of Biosimilar
Portfolio
Exceptional Performance of Global Operations Delivers on

Market Opportunities, Customer Service, Cost Control
2014 Forecast GAAP to Non-GAAP Reconciliation

Forecast for Twelve Months
Ending December 31, 2014
Low
High
GAAP to Non-GAAP net income calculation

GAAP net income
456
544
Adjusted for:
Amortization
1,649
Global supply chain initiative

Acquisition and licensing charges
Interest accretion on contingent liability
1,649
40
40
341
341
20
20
Non-cash impairment charges and asset sales
Non-recurring (gains) losses and early retirement of debt
(50)
(50)
Legal settlements
Income taxes on items above
(245)
Adjusted Non-GAAP net income
(245)
2,212
2,300
Diluted earnings per share

Earnings per share - GAAP
2.60
3.10
Diluted earnings per share - Non-GAAP
12.60
13.10
Basic weighted average common shares outstanding
175.5
175.5
Diluted weighted average common shares outstanding
175.5
175.5

Low
High
GAAP net income
456
544
Plus:
Interest expense
295
(2)
Interest income
Provision for income taxes
Depreciation (includes accelerated depreciation)
Amortization
EBITDA
Adjusted for:
Global supply chain initiative
Non-cash impairment charges and asset sales
Non-recurring (gains) losses and early retirement of debt
Legal settlements
Share-based compensation
Adjusted EBITDA
295
(2)
205
221
204
204
1,649
2,807
1,649
2,911
3
341
(50)
50
$
3,151
3
341
(50)
50
$
3,255

Reconciliation of Adjusted Gross Margin
Low
High
Actavis Pharma GAAP Gross Margin %
59.8%
62.8%
0.5%
0.5%
2.7%
2.7%
Actavis Pharma Non-GAAP Gross Margin %
63.0%
66.0%
Adjusted for:
Global supply chain charges
Reconciliation of GAAP to Non-GAAP SG&A

Forecast for Twelve Months Ending
December 31, 2014
Low
Actavis Pharma GAAP SG&A % of Revenue
High
21.7%
23.2%
0.7%
0.7%
21.0%
22.5%
Adjusted for:
Actavis Pharma Non-GAAP SG&A % of Revenue

Actavis Investor Day 013114

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Actavis Investor Day 013114

Uploaded by

Copyright:

Available Formats

Lisa

Actavis Cautionary Statement Regarding Forward-Looking Statements

Exceptional Cash Flow

Significant 1 Year Progress Against Objective

Created Top 20 global pharmaceutical

Gastroenterology and Dermatology

Substantial operational synergies coupled

Focus on 2014 - Pillars of Growth

Commercial Strength Maximize value of current business

Organic Growth Invest in focused Gx, Rx, Biosimilar R&D;

Operational Excellence Focus on quality, efficiency, synergy

Business Development Define opportunities that enhance

New Leadership Structure

New Leadership Structure and Functions

Global Commercial Sales

Aligning Management to Support Pillars of Growth

Redefining R&D Structure to Capitalize on Capabilities while Maintaining

Redefining Responsibility of Global Operations Organization

2014 Segment & Revenue Reporting Structure

* Reporting in each category:

Agenda: Actavis Pharma

Global Organization 2013 Highlights

North American Specialty Brands

2014 Objectives and Outlook

Actavis Commercial Organization Structure

Specialty Commercial Structure Maximizes Growth Potential

Many markets are hybrids of Rx, Gx,

Common commercial platform

Synergies exist in the support

Rx segment will continue to grow as

Actavis and Warner Chilcott Integrations

G&A / Shared services

2013 Significant Accomplishments

Strong growth in U.S. generics holding #1 or #2 market positions throughout the

Optimized International commercial structure and regional focus for future

Foundation for Global Specialty Pharma

Generics and Specialty Brands

Generics and OTC

Third-party business (alone)

North American Specialty Brands 2013 Overview

* Q4 Data is based on preliminary results

North American Specialty Brands

Significant Potential New Product Opportunities From Existing Pipeline

Specialty Brands Expansion Further Diversifies Actavis

Actavis Specialty Contribution

* Includes 4th Quarter Sales of Warner Chilcott

Specialty Brands Highlights

Strong Portfolio of US Marketed Products

U.S. Sales Force

Strategic Account Specialists:

Total U.S. Sales Force: 750

2013 N.A. Specialty Sales by Franchise

2013 N.A. Specialty Proforma*

* Based on Proforma Sales for Warner Chilcott

CONTRACEPTIVES: $600+ Million Franchise in the U.S.

Source: IMS Health

Share of Promoted Oral Contraceptives is growing

Leading portfolio in Womens Health includes leading infertility and

#1 Prescribed HRT for new patients

Continue to Grow Rapaflo

Source: IMS Health NPA Quarterly and Weekly TRx Data

Some share lost during

Source: IMS Health Weekly TRx

2013 Weekly TRx